Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Adagio Therapeutics on Thursday, setting a price target of $46, which is approximately 224.40% above the present share price of $14.18.
Yee expects Adagio Therapeutics to post earnings per share (EPS) of -$0.98 for the fourth quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Hold rating of shares in Adagio Therapeutics, with an average price target of $22.
The analysts price targets range from a high of $46 to a low of $9.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$60.42 million. The company's market cap is $1.58 billion.
According to TipRanks.com, Jefferies analyst Michael Yee is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 2.0% and a 43.94% success rate.
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.